Robert W. Baird Initiates Coverage on Pliant Therapeutics (NASDAQ:PLRX)

Robert W. Baird assumed coverage on shares of Pliant Therapeutics (NASDAQ:PLRX – Get Rating) in a research report sent to investors on Wednesday morning, The Fly reports. The brokerage issued an outperform rating and a $44.00 price target on the stock. Other equities research analysts also recently issued reports about the company. Citigroup cut their […]

Related Keywords

Canada ,United States ,Stifel Nicolaus ,Robertw Baird ,Bernard Coulie ,Eric Lefebvre ,Jpmorgan Chase Co ,Quantamental Technologies ,Securities Exchange Commission ,Citigroup ,Management Company Inc ,Cubist Systematic Strategies ,Bessemer Group Inc ,Royal Bank ,Blackstone Inc ,Pliant Therapeutics Inc ,Pliant Therapeutics ,Get Rating ,Exchange Commission ,Systematic Strategies ,Pliant Therapeutics Daily ,Nasdaq Plrx ,Plrx ,Medical ,Initiated Coverage ,